首页> 外国专利> METHOD FOR DETERMINING FIBRINOGEN DURING RECALCIFICATION OF CITRATE PLASMA AND EVALUATING ITS FUNCTIONALITY

METHOD FOR DETERMINING FIBRINOGEN DURING RECALCIFICATION OF CITRATE PLASMA AND EVALUATING ITS FUNCTIONALITY

机译:柠檬酸血浆再定型测定纤维蛋白原及其功能的方法

摘要

FIELD: medicine.;SUBSTANCE: invention refers to medicine, namely to laboratory diagnostics and can be used for determination of fibrinogen in recalcification of citrate plasma and evaluation of its functionality. Essence of method consists in recalcification of blood plasma with calcium chloride with subsequent registration of degree of coagulation on photometer for enzyme immunoassay. In order to increase the accuracy of the test, polyethylene glycol with a molecular weight of 3350 is used as an activator of the fibrin stabilizing factor. Reaction is started in parallel 2 series by adding 0.25 M calcium chloride solution to sample containing citrate plasma, PEG-3350 and VBS buffer with pH 7.4, thoroughly mixed, absorbance of samples is measured, then incubated for 60 min at 37 °C, in the first series of the experiment, the protein content in the fibrin clot is determined by a standard method using a biuret reagent, in the second series of experiments, the plasma coagulation is determined photometrically by changing the turbidity of the samples at wavelength of 450 nm with measurement intervals of 0 and 60 min, fibrinogen content is calculated by formula: FG (g/l) = ΔA450×5.12, where: ΔA450 – change of optical density of sample in second series, with plasma coagulation; 5.12 is a coefficient for transfer of changes in optical density of the sample when plasma coagulation is in g/l, which is the ratio of protein in the fibrin clot to change in optical density in the sample during plasma coagulation, calculating fibrinogen functionality as a difference between fibrinogen values determined by this method and using the Claus method, calculating difference in % of protein in fibrin clot and difference of more than 10 % is defined as impaired functionality of fibrinogen.;EFFECT: using this method enables determining the amount of fibrinogen and its functionality, which enables to conduct wide screening and detect people prone to thrombosis.;1 cl, 5 tbl, 1 dwg
机译:技术领域本发明涉及医学,即实验室诊断学,并且可用于在柠檬酸盐血浆的再钙化中测定纤维蛋白原并评估其功能性。该方法的实质在于用氯化钙重新钙化血浆,随后在光度计上记录凝结度以进行酶免疫测定。为了提高测试的准确性,使用分子量为3350的聚乙二醇作为血纤蛋白稳定因子的活化剂。通过将0.25 M氯化钙溶液添加到含有柠檬酸血浆,PEG-3350和pH 7.4的VBS缓冲液的样品中,以2个平行系列开始反应,充分混合,测量样品的吸光度,然后在37°C下温育60分钟。在第一个系列实验中,使用缩二脲试剂通过标准方法确定血纤蛋白凝块中的蛋白质含量,在第二个系列实验中,通过改变450 nm波长处的浊度通过光度法测定血浆凝结测量间隔为0和60分钟时,纤维蛋白原含量的计算公式为:FG(g / l)=ΔA 450 ×5.12,其中:ΔA 450 –光学变化第二系列样品的密度,血浆凝结; 5.12是血浆凝结度以g / l为单位时样品光密度变化的转移系数,这是血浆凝结过程中血纤蛋白凝块中蛋白质与样品光密度变化的比值,计算纤维蛋白原功能为这种方法和使用Claus方法测定的纤维蛋白原值之间的差异,计算纤维蛋白凝块中蛋白质百分比的差异和大于10%的差异被定义为纤维蛋白原功能受损。;效果:使用此方法可以确定纤维蛋白原的量及其功能,可以进行广泛的筛查并检测容易形成血栓的人。; 1 cl,5 tbl,1 dwg

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号